

Effects of Creative Arts Therapies on Psychological Symptoms and Quality of Life in Patients With Cancer

Timothy W. Puetz, PhD, MPH; Christopher A. Morley, MPH; Matthew P. Herring, PhD

Importance: Creative arts therapies (CATs) can reduce anxiety, depression, pain, and fatigue and increase quality of life (QOL) in patients with cancer. However, no systematic review of randomized clinical trials (RCTs) examining the effects of CAT on psychological symptoms among cancer patients has been conducted.

Objectives: To estimate the effect of CAT on psychological symptoms and QOL in cancer patients during treatment and follow-up and to determine whether the effect varied according to patient, intervention, and design characteristics.

Evidence Review: We searched ERIC, Google Scholar, MEDLINE, PsycInfo, PubMed, and Web of Science from database inception to January 2012. Studies included RCTs in which cancer patients were randomized to a CAT or control condition and anxiety, depression, pain, fatigue and/or QOL were measured pre- and post-intervention. Twenty-seven studies involving 1576 patients were included. We extracted data on effect sizes, moderators, and study quality. Hedges *d* effect sizes were computed, and random-effects models were used to estimate sampling error and population variance.

Findings: During treatment, CAT significantly reduced anxiety ($\Delta=0.28$ [95% CI, 0.11-0.44]), depression ($\Delta=0.23$ [0.05-0.40]), and pain ($\Delta=0.54$ [0.33-0.75]) and increased QOL ($\Delta=0.50$ [0.25-0.74]). Pain was significantly reduced during follow-up ($\Delta=0.59$ [95% CI, 0.42-0.77]). Anxiety reductions were strongest for studies in which (1) a non-CAT therapist administered the intervention compared with studies that used a creative arts therapist and (2) a waiting-list or usual-care comparison was used. Pain reductions were largest during inpatient treatment and for homogeneous cancer groups in outpatient settings; significantly smaller reductions occurred in heterogeneous groups in outpatient settings.

Conclusions and Relevance: Exposure to CAT can improve anxiety, depression, and pain symptoms and QOL among cancer patients, but this effect is reduced during follow-up.

JAMA Intern Med. 2013;173(11):960-969.

Published online May 13, 2013.

doi:10.1001/jamainternmed.2013.836

APPROXIMATELY 40% OF adults in the United States report using at least 1 complementary and alternative medicine (CAM) therapy, with prevalence estimates among patients with cancer ranging from 18% to 91%.¹⁻⁷ Various CAM therapies have improved psychological symptoms frequently associated with cancer and cancer treatment, including cancer-related fatigue,⁸ pain,⁹ and symptoms of anxiety and depression.^{10,11}

Creative arts therapies (CATs), including music therapy,¹²⁻¹⁴ dance/movement therapy,¹⁵⁻¹⁸ and various forms of art therapy,¹⁹⁻²¹ have received less empirical attention than other CAM therapies more commonly used among adults, such as vitamin and nonvitamin supplements and

mind-body therapies.¹ Although CAT research has been predominately qualitative, clinical research on CAT has expanded from purely observational science to a wider, cross-disciplinary approach that includes fields such as neuropsychiatry.^{16,22} Prior reviews have suggested that

See Invited Commentary at end of article

CAT may be a useful adjuvant therapy to improve cancer- and treatment-related symptoms during and after treatment.^{23,24} For example, recent systematic reviews of CAT among cancer patients concluded that music interventions may have beneficial effects on anxiety, pain, and mood, whereas music and dance therapies may improve quality of life (QOL).^{15,25} However, no sys-

Author Affiliations: Office of the Director, National Institutes of Health, Bethesda, Maryland (Dr Puetz); The ArtReach Foundation, Atlanta, Georgia (Mr Morley); and Department of Epidemiology, University of Alabama at Birmingham (Dr Herring).

tematic review of randomized clinical trials (RCTs) examining the effects of CAT on psychological symptoms among cancer patients has been conducted.

This systematic review used the results of RCTs to evaluate the effect of exposure to CAT on psychological symptoms and QOL among patients with cancer. The aims of this meta-analysis were to estimate the effect size of exposure to CAT on psychological symptoms (ie, anxiety, depression, pain, cancer-related fatigue) and on QOL among cancer patients during and after treatment and to determine how potential moderators may influence the efficacy of CAT during and after cancer treatment.

METHODS

DATA SOURCES AND SEARCHES

The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.²⁶ Electronic searches of databases were conducted via ERIC (Educational Resource Information Center), Google Scholar, MEDLINE, PsycInfo, PubMed, and Web of Science from database inception to January 2012 using the search terms *cancer* and (*anxiety* or *depression* or *pain* or *fatigue* or *quality of life*) and (*art* or *art therapy* or *creative arts therapy* or *dance* or *drama* or *music* or *writing*). Searches were restricted to English-language RCTs. Supplemental searches of reference lists from retrieved articles were performed manually.

STUDY SELECTION

Included studies compared CAT with no treatment, waiting list, usual care, or placebo control in cancer patients regardless of age, sex, cancer type, cancer stage, or treatment type. Patients could have been receiving treatment, in long-term follow-up, or receiving palliative care. Interventions could take place in an inpatient or outpatient setting and be group or individual based. The authors considered art, dance, drama, music, writing, or combined creative arts modalities. Outcomes included measures of anxiety, depression, pain, fatigue, and/or QOL assessed before and during and/or after exposure to CAT.

Excluded studies explicitly examined mind-body techniques (eg, yoga,




Figure 1. Flowchart of study selection. CAT indicates creative arts therapies; k, number of effects; QOL, quality of life; and RCT, randomized clinical trial.

meditation, qigong) without including additional features of CAT and/or compared CAT only with an active therapy (eg, pharmacotherapy, counseling). A flowchart of study selection is presented in **Figure 1**.

DATA EXTRACTION AND QUALITY ASSESSMENT

The authors independently extracted data and resolved discrepancies by consensus judgment. Effect sizes were calculated by subtracting the mean change in the control condition from the mean change in the treatment condition and dividing the difference by the pooled standard deviation of preintervention scores.²⁷ Effect sizes were adjusted using the Hedges small-sample bias correction and calculated so that decreased anxiety, depression, pain, and fatigue and increased QOL resulted in positive effect sizes.²⁶ When precise means were not reported, effect sizes were estimated²⁸ from *F* tests²⁹ or Figures.^{30,31} When precise standard deviations were not reported,³¹⁻³⁴ the standard deviation was drawn from published norms or the largest other study using the same measure.

Study quality was assessed using a 15-item scale³⁵ and addressed randomiza-

tion, sample selection, quality of outcome measures, and statistical analysis. Quality assessment was independently performed by the authors (T.W.P. and M.P.H.) and showed high concordance between raters (intraclass correlation coefficient [3,2], 0.94 [95% CI, 0.87-0.99]).³⁶ According to the Bland-Altman method for limits-of-agreement,^{37,38} the mean disagreement was close to zero (−0.22 [95% CI, −0.05 to −0.40]), suggesting no evidence for systematic disagreement bias. Quality scores were not used as weights or moderators because of the potential disparity in results that depends on the specific quality scale used.³⁹

DATA SYNTHESIS AND ANALYSIS

To better understand the effect of exposure to CAT on psychological symptoms and QOL during the course of treatment and recovery, separate analyses were performed for investigations assessing anxiety, depression, fatigue, pain, and QOL. Analyses were further subdivided by posttreatment and follow-up outcomes.

The MeanES macro (SPSS, version 19.0; SPSS, Inc) was used to calculate the aggregated mean effect size delta value

Table 1. Characteristics of Included Trials

Characteristic	Outcome Measure									
	Anxiety		Depression		Pain		Fatigue		Quality of Life	
	Posttreatment	Follow-up	Posttreatment	Follow-up	Posttreatment	Follow-up	Posttreatment	Follow-up	Posttreatment	Follow-up
Study Characteristics										
Effects, k	25	5	11	5	18	7	7	2	6	6
Total sample, No.	1413	246	584	246	1237	750	359	102	275	359
Patient Characteristics^a										
Age, mean (SD), y	52.7 (10.7)	54.3 (3.1)	54.27 (3.3)	54.3 (3.1)	49.7 (16.0)	48.6 (9.6)	55.0 (2.6)	53.5 (1.9)	56.9 (6.3)	55.0 (4.3)
Female sex, %	60.5	90.7	76.7	90.7	59.3	85.7	56.6	76.8	91.7	100
Cancer site, %										
Blood	21.9	72.0	14.4	72.0	18.2	...	22.3	67.6
Breast	44.2	28.0	52.5	28.0	42.4	96.0	31.7	32.4	70.9	100.0
Colorectal	3.7	...	4.2	...	1.9	...	5.8
Gynecologic	2.8	...	5.1	...	2.3	...	3.2
Head and neck	3.1	...	4.9	...	10.4	...	9.1
Kidney	3.3	...	7.4	13.6
Lung	8.9	...	2.8	...	3.8	...	5.2
Prostate	7.0	...	2.8	...	5.1	4.0	5.2
Other	5.1	...	6.0	...	15.9	...	3.9	...	29.1	...
Cancer treatment, %										
Surgery	30.2	42.7	34.5	32.9	63.2	96.0	40.3	85.3	32.1	...
Chemotherapy	41.5	17.5	10.6	20.5	6.3	...	15.6	...	28.3	12.9
Radiotherapy	23.9	17.9	42.0	21.0	17.3	4.0	39.4	...	26.7	13.2
Hormone therapy	1.5	7.3	4.2	8.6	9.6	...
Combination therapy	2.9	14.6	8.7	17.1	13.1	...	4.7	14.7	3.2	73.9
Baseline T score, mean (SD)	49.2 (7.8)	48.3 (3.0)	53.4 (8.1)	47.2 (7.3)	41.15 (6.9)	46.1 (3.7)	59.1 (5.4)	58.3 (4.3)	52.5 (7.9)	51.8 (8.3)

Abbreviation: ellipses, not applicable because the category was not reported.

^aPercentages have been rounded and might not total 100.

(Δ), associated 95% confidence interval, and sampling error variance according to a random-effects model.⁴⁰ We used random-effects models to account for between-studies heterogeneity associated with study-level sampling error and population variance.⁴⁰ Each effect was weighted by the inverse of its variance and reestimated after the random-effects variance component was added.³¹ Heterogeneity and consistency were evaluated with the *Q* statistic and the *I*² statistic, respectively.⁴¹ Heterogeneity also was examined relative to observed variance and was indicated if the sampling error accounted for less than 75% of the observed variance.²⁷ Publication bias was addressed by inspection of a funnel plot⁴² and quantified with rank correlation and regression methods.^{42,43}

Primary Moderators Analysis

To provide focused research hypotheses about the effects of exposure to CAT on treatment symptoms among cancer patients,⁴⁴ primary moderators were selected for each model that met criteria for heterogeneity of effects. Variable selection was based on logical, theoretical, or prior empirical relation to CAT and outcomes. Two variables were selected for the anxiety model (ie, therapeutic monitoring and comparison type). Three variables were selected for the pain model (ie, intervention setting, homo-

geneity of the cancer group, and the intervention setting \times homogeneity of group interaction). Variable definitions are provided in eTable 1 (<http://www.jamainternalmed.com>).

Using the MetaReg macro (SPSS, version 19.0), primary moderator variables were included in a weighted, least-squares, multiple regression analysis with maximum-likelihood estimation^{27,40} adjusted for nonindependence of multiple effects contributed by single studies.⁴⁵ Test results of the regression model (the *Q*_R statistic) and its residual error (the *Q*_E statistic) are reported. Significant categorical moderators were decomposed using a random-effects model to compute mean effect sizes and 95% confidence intervals.⁴⁰

Secondary Moderators Analysis

Secondary moderators were selected for descriptive, univariate analyses based on logical, theoretical, or prior empirical relation with CAT and/or outcomes and grouped into participant characteristics, intervention characteristics, and study design characteristics. Variable definitions are provided in eTable 1. We computed mean effect sizes and 95% confidence intervals for continuous and categorical variables using a random-effects model.⁴⁰

RESULTS

Twenty-seven trials of 1576 patients were included in the meta-analysis and are presented in the eReferences. Characteristics of these trials and study quality assessment are presented in **Table 1**. Variables of CAT are provided in **Table 2**. Funnel plots for all models were inspected and found to be roughly symmetrical (eFigure). The Begg rank correlation and Egger regression analyses were not statistically significant for any model, suggesting absence of publication bias (eTable 2).

ANXIETY

Postintervention

Anxiety was significantly reduced after exposure to CAT interventions ($\Delta = 0.28$ [95% CI, 0.11-0.44]; $z = 3.26$ [$P = .001$]). Distribution of the 25 effects is presented in **Figure 2A**. The effect was heterogeneous ($Q_{\text{Total}(24)} = 56.65$ [$P < .001$]). Sampling error accounted for 44.0% of the observed variance. The effect was moderately consistent across stud-

Table 2. CAT Intervention Characteristics^a

Characteristic	Outcome Measure									
	Anxiety		Depression		Pain		Fatigue		Quality of Life	
	Post-treatment	Follow-up	Post-treatment	Follow-up	Post-treatment	Follow-up	Post-treatment	Follow-up	Post-treatment	Follow-up
Setting, %										
Inpatient	8.0	20.0	9.1	20.0	44.4	85.7	14.3	50.0	0	0
Outpatient	92.0	80.0	90.9	80.0	55.6	14.3	85.7	50.0	100.0	100.0
Monitoring, %										
Therapist present	28.0	60.0	72.7	60.0	16.7	0	57.1	50.0	100.0	50.0
No therapist present	72.0	40.0	27.3	40.0	83.3	100.0	42.9	50.0	0	50.0
Modality ^b										
Art	12.0	20.0	27.3	12.0	5.6	...	14.3	...	16.7	16.7
Dance	8.0	40.0	18.2	8.0	14.3	50.0	33.3	...
Music	72.0	40.0	45.5	72.0	88.9	85.7	57.1	50.0	50.0	33.3
Writing	8.0	...	9.1	8.0	5.6	14.3	14.3	50.0
Program length, mean (SD), wk	5.5 (3.0)	7.0 (4.6)	5.9 (3.3)	7.0 (4.6)	5.8 (2.5)	6.4 (2.4)	4.5 (1.1)	4.5 (2.1)	9.3 (4.9)	5.5 (5.9)
Program session duration, mean (SD), min	53.4 (52.3)	107.5 (84.1)	77.0 (66.0)	107.5 (84.1)	39.9 (32.8)	28.6 (3.8)	55.7 (1.1)	102.5 (109.6)	71.3 (33.3)	45.0 (43.3)
Program frequency, mean (SD), d/wk	1.0 (0.4)	0.8 (0.4)	0.9 (0.3)	0.8 (0.4)	5.2 (2.7)	6.6 (1.1)	1.0	1.0	1.2 (0.7)	2.4 (1.8)
Retention rate, median (range), %	100 (8.0-100.0)	94.4 (57.1-100.0)	94.4 (57.1-100.0)	94.4 (57.1-100.0)	100.0 (81.8-100.0)	100.0 (90.0-100.0)	100.0 (90.5-100.0)	97.2 (94.4-100.0)	91.0 (57.1-100.0)	84.4 (57.1-100.0)
Adherence, median (range), %	95.0 (25.0-100.0)	90.0	88.0 (86.0-90.0)	90.0	100 (96.9-100.0)	100	93.0 (86.0-100.0)	...	90.0	97.6 (90.0-97.6)
Study quality, mean (SD), rating ^c	10.2 (2.2)	11.5 (2.6)	11.1 (2.0)	11.5 (2.6)	11.8 (1.5)	12.6 (1.1)	10.4 (2.5)	11.5 (2.8)	10.3 (3.0)	11.0 (3.1)

Abbreviations: CAT, creative arts therapy; ellipses, not applicable because the category was not reported.

^aPercentages have been rounded and might not total 100.

^bBased on the number of studies identified with the criteria matching the trial type.

^cBased on randomization, sample selection, quality of outcome measures, and statistical analysis as described in the Data Extraction and Quality Assessment subsection of the Methods section.

ies ($I^2 = 59.4\%$ [95% CI, 49.2%-67.6%]).

The overall multiple regression model for anxiety was significantly related to effect size ($Q_{R(3)} = 17.44$ [$P < .001$]; $R^2 = 0.41$; $Q_{E(21)} = 24.76$ [$P = .26$]). Therapeutic monitoring ($\beta = 0.46$; $z = 2.99$ [$P = .003$]) and type of comparison ($\beta = 0.51$; $z = 3.12$ [$P = .002$]) were independently related to effect size. When the number of effects allowed decomposition of these variables, larger improvements were found for studies in which (1) the intervention was administered by a non-CAT therapist ($\Delta = 0.32$ [95% CI, 0.13-0.51]) compared with those delivered by a CAT therapist ($\Delta = 0.17$ [-0.12 to 0.46]) and (2) a waiting-list or usual-care comparison ($\Delta = 0.37$ [0.20-0.54]) compared with a

placebo condition was used ($\Delta = -0.04$ [-0.35 to 0.28]).

Follow-up

Anxiety was not significantly reduced during the period after exposure to CAT interventions ($\Delta = 0.08$ [95% CI, -0.26 to 0.42]; $z = 0.46$ [$P = .64$]). Distribution of the 5 effects is presented in Figure 2A. The effect was homogeneous ($Q_{Total(4)} = 6.92$ [$P = .14$]). Sampling error accounted for 58.3% of the observed variance. The effect was moderately consistent across studies ($I^2 = 56.7\%$ [95% CI, 24.8%-75.0%]).

DEPRESSION

Posttreatment

Depression was significantly reduced after exposure to CAT inter-

ventions ($\Delta = 0.23$ [95% CI, 0.05-0.40]; $z = 2.49$ [$P = .01$]). Distribution of the 11 effects is presented in Figure 2B. The effect was homogeneous ($Q_{Total(10)} = 11.47$ [$P = .32$]). Sampling error accounted for 87.3% of the observed variance. The effect was consistent across studies ($I^2 = 21.5\%$ [95% CI, 0.0%-45.1%]).

Follow-up

Depression was not significantly reduced during the period after exposure to CAT interventions ($\Delta = -0.09$ [95% CI, -0.42 to 0.22]; $z = 0.61$ [$P = .54$]). Distribution of the 5 effects is presented in Figure 2B. The effect was homogeneous ($Q_{Total(4)} = 6.16$ [$P = .19$]). Sampling error accounted for 65.2% of the observed variance.




Figure 2. Forest plots of the unweighted distribution of Hedges *d* effect sizes (95% confidence intervals) for studies assessing anxiety (A) and depression (B).

The effect was moderately consistent across studies ($I^2 = 51.2%$ [95% CI, 15.6%-72.0%]).

PAIN

Posttreatment

Pain was significantly reduced after exposure to CAT interventions ($\Delta = 0.54$ [95% CI, 0.33-0.75]; $z = 5.04$ [$P < .001$]). Distribution of the 18 effects is presented in **Figure 3A**. The effect was heterogeneous ($Q_{\text{Total}(17)} = 52.15$ [$P < .001$]). Sampling error accounted for 36.5% of the observed variance. The effect was moderately consistent across studies ($I^2 = 69.3%$ [95% CI, 60.6%-76.1%]).

The overall multiple regression model for pain was significantly re-

lated to effect size ($Q_{R(4)} = 33.98$ [$P < .001$]; $R^2 = 0.65$; $Q_{E(13)} = 18.07$ [$P = .16$]). The intervention setting \times homogeneity of patient interaction was independently related to effect size ($\beta = 0.71$; $z = 1.30$ [$P = .02$]). Significantly smaller effects were found in studies with heterogeneous cancer groups exposed to CAT in outpatient settings ($\Delta = 0.10$ [95% CI, -0.12 to 0.31]) compared with the average effect for all other groups ($\Delta = 0.81$ [0.65-0.96]; $Q_{\text{Between}(1)} = 27.95$ [$P < .001$]) (**Figure 4**).

Follow-up

Pain was significantly reduced during the period after exposure to CAT interventions ($\Delta = 0.59$ [95% CI, 0.42-0.77]; $z = 6.51$ [$P < .001$]).

Distribution of the 7 effects is presented in **Figure 3A**. The effect was homogeneous ($Q_{\text{Total}(6)} = 8.59$; $P = .20$). Sampling error accounted for 70.3% of the observed variance. The effect was consistent across studies ($I^2 = 41.8%$ [95% CI, 7.5%-63.4%]).

FATIGUE

Fatigue was not significantly reduced after exposure to CAT interventions ($\Delta = 0.16$ [95% CI, -0.04 to 0.37]; $z = 1.54$ [$P = .12$]). Distribution of the 7 effects is presented in **Figure 3B**. The effect was homogeneous ($Q_{\text{Total}(6)} = 2.22$ [$P = .90$]). Sampling error accounted for 99.9% of the observed variance. The effect was consistent across studies ($I^2 = 0.0%$ [95% CI, 0.0%-7.6%]).




Figure 3. Forest plots of the unweighted distribution of Hedges *d* effect sizes (95% confidence intervals) for studies assessing pain (A) and fatigue (B). NA indicates not applicable.

QUALITY OF LIFE

Posttreatment

Quality of life was significantly increased after exposure to CAT interventions ($\Delta = 0.50$ [95% CI, 0.25-0.74]; $z = 3.98$ [$P < .001$]). Distribution of the 6 effects is presented in **Figure 5**. The effect was homogeneous ($Q_{\text{Total}(5)} = 5.09$ [$P = .41$]). Sampling error accounted for 98.1% of the observed variance. The effect was consistent across studies ($I^2 = 21.4%$ [95% CI, 0.0%-49.1%]).

Follow-up

Quality of life was not significantly increased during the period after exposure to CAT interventions ($\Delta = 0.22$ [95% CI, -0.09 to 0.54]; $z = 1.40$ [$P = .16$]). Distribution of 6 of the effects are presented in Figure 5. The effect was homogeneous ($Q_{\text{Total}(5)}$

$= 10.11$; $P = .16$). Sampling error accounted for 52.7% of the observed variance. The effect was moderately consistent across studies ($I^2 = 60.4%$ [95% CI, 35.4%-75.8%]).

SECONDARY MODERATORS

The number of effects (*k*), mean effect size (Δ), 95% confidence interval, *P* value, and I^2 value for each level of each moderator for the anxiety, depression, pain, fatigue, and QOL models are presented in eTables 3 through 7, respectively. These results represent descriptive, univariate analyses and should be interpreted accordingly.

DISCUSSION

The cumulative evidence summarized in this review indicates that exposure to CAT reduces symptoms of anxiety, depression, and pain and




Figure 4. Interaction of cancer group (homogeneous vs heterogeneous) and intervention setting. Error bars indicate standard error.

improves QOL among cancer patients after treatment. The magnitude of the effects is generally diminished during follow-up. Exposure to CAT did not significantly reduce symptoms of fatigue after treatment or during follow-up (**Figure 6**). These findings are consistent with the findings of previ-




Figure 5. Forest plot of the unweighted distribution of Hedges *d* effect sizes (95% confidence intervals) for studies related to quality of life.




Figure 6. Mean delta effect size for posttreatment and follow-up assessments across psychological symptoms and quality of life. * $P < .05$.

ous reviews of the positive effects of CAT on anxiety, pain, mood, and QOL among cancer patients.^{15,25} The magnitude of the overall effects of CAT exposure on symptoms of anxiety, depression, pain, and QOL was small but similar to improvements reported for other CAM therapies among cancer patients, including (1) mindfulness-based therapy on anxiety and depression⁶²; (2) acupuncture and massage therapy on pain intensity⁶³; (3) yoga on anxiety, depression, and QOL^{46,64}; and (4) exercise on anxiety,⁶⁵ depression,^{66,67} and QOL.⁶⁸ The effects of CAT exposure on cancer-related fatigue is more difficult to interpret. These effects may be modality dependent such that movement-based creative expression has effects more

comparable to those seen in exercise studies than other CAT modalities.^{15,69,70} Although exposure to CAT elicited significant improvements in depression and QOL, the mean effects were found to be homogeneous and therefore were not subjected to moderator analyses. Significant findings for anxiety and pain are discussed in the following sections.

ANXIETY

Anxiety reduction was strongest for studies in which (1) the intervention was administered by a non-CAT therapist and (2) a waiting-list or usual-care comparison was used. Why larger anxiety reductions resulted from CAT interven-

tions not administered by CAT therapists is uncertain. Treatment differences may result from interventions administered by CAT therapists who have undergone the rigorous training and credentialing expected of nationally certified CAT therapists compared with interventions administered by non-CAT therapists. Another possibility is related to the need to reduce tension in the perceived polarization of CAM and biomedicine in medical settings. Such tension can be an important factor in shaping cancer patients' first impressions and influencing their confidence in CAM practices.⁷¹⁻⁷³ Although openness to experience may predicate the use of provider-directed CAM, clinical distress has predicated the use of self-directed CAM.⁷⁴ This perception of openness is likely related to a need for better integration of CAM and conventional medicine in medical settings. Patients do not necessarily expect clinicians to believe in the philosophy of CAM, but they do want medical approval and to know that their CAM choices are reasonable and safe.^{72,73} Therefore, material used by practitioners to explain CAM to potential patients should avoid challenging patients' beliefs about the perceived disadvantages and instead focus on the positive and preventive effects of CAM.⁷⁵

Larger anxiety reductions also resulted from investigations that used a waiting-list or usual-care control condition rather than a placebo control. Our analysis did not permit a rigorous decomposition of this effect. However, these findings suggest that future well-designed trials may benefit from the use of a waiting-list or usual-care comparison in addition to intervention and placebo conditions to control for differences in expectancy, conditioning, and meaning.^{76,77} Previous studies have highlighted the need to examine the placebo effect in alternative medicine.⁷⁷⁻⁷⁹ Researchers need to focus on factors that influence expectancy and possible mediators of the placebo effect. For example, younger women with a higher level of education and patients with greater clinical distress or a longer duration after cancer di-

agnosis are more likely to use CAM and critically engage clinicians regarding CAM and biomedical care.^{71,80} These issues of expectancy are at least partially independent of known direct biological effects of interventions and require improving clinical trial design and interpretation of nonspecific healing responses that constitute the placebo effect.

PAIN

Pain reduction was largest for studies conducting interventions during inpatient treatment and with homogeneous cancer groups in outpatient settings. Significantly smaller reductions occurred in heterogeneous cancer groups in outpatient settings. We are uncertain why less pain reduction resulted from CAT interventions in heterogeneous cancer groups in outpatient settings. One possibility is that the openness to experience predicated the use of provider-directed CAM.⁷⁴ For example, inpatient and outpatient consultation services have shown success in addressing questions raised by the possible integration of CAM therapies with conventional care, particularly among patients who have severe, chronic, or incurable conditions and likely need inpatient facilities.⁸¹ This type of integration may explain the similar effects found in inpatient groups. The differential effect of cancer groups in outpatient settings is more difficult to interpret. Complementary and alternative medicine therapies might be more useful in augmenting traditional analgesic therapy in certain cancer outpatient groups who cannot tolerate or may be reluctant to take pain medications.⁶³ Integrated services may be highly valued by these types of cancer patients who have traditionally preferred their complementary health care to be provided in a nonmedicalized environment.⁷² Prior reviews have provided striking observations about the paucity of well-designed trials evaluating CAM interventions for cancer-related pain.⁹ Because the available literature suggests a large degree of heterogeneity regarding the design and administration of CAT related to

cancer-related pain, the present findings may be particularly noteworthy with regard to methodological issues within CAT research.

LIMITATIONS

The included trials had notable limitations. Many lacked well-validated symptom assessments among cancer patients⁸² and adequate information regarding features of the intervention, appropriateness of comparisons, adherence rates, and medication use. These limitations emphasize the importance of adoption of and adherence to reporting guidelines to improve the quality of future trials. To inform the design of appropriate CAT interventions and offer insight into putative biopsychosocial mechanisms of symptom reduction during and after cancer treatment, well-designed RCTs should (1) seek to better characterize the features of the CAT intervention (ie, certified instruction, frequency, session duration, program length, and modality); (2) examine CAT exposure on the interrelationship between neurobiological and psychological measures of cancer symptoms; and (3) investigate the mechanistic similarities, differences, and interactions among various CAT modalities, psychosocial interventions, and pharmacologic treatments used to improve psychological symptoms in patients with cancer.

CONCLUSIONS

This systematic review offers a unique look into the potential benefits of CAT that may guide further hypothesis-driven investigation into adjuvant treatments to improve conventional disease management. The cumulative evidence indicates that CAT can decrease symptoms of anxiety, depression, and pain and increase QOL among cancer patients after treatment. The effects are greatly diminished during follow-up. Future well-designed RCTs are needed to address the methodological heterogeneity found within this field of research.

Accepted for Publication: January 26, 2013.

Published Online: May 13, 2013. doi: 10.1001/jamainternmed.2013.836

Correspondence: Matthew P. Herring, PhD, Department of Epidemiology, University of Alabama at Birmingham, 1530 Third Ave S, Ryals Public Health Bldg 210E, Birmingham, AL 35294 (mph8@uab.edu).

Author Contributions: Dr Puetz had full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Puetz. Acquisition of data: Puetz and Herring. Analysis and interpretation of data: Puetz, Morley, and Herring. Drafting of the manuscript: Puetz, Morley, and Herring. Critical revision of the manuscript for important intellectual content: Puetz, Morley, and Herring. Statistical analysis: Puetz and Herring. Administrative, technical, or material support: Puetz and Morley. Supervision: Puetz and Herring.

Conflict of Interest Disclosures: None reported.

Online-Only Material: The eReferences, eTables, and eFigure are available at <http://www.jamainternalmed.com>.

REFERENCES

1. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Report*. 2008;10(12):1-23.
2. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. *Int J Clin Pract*. 2012; 66(10):924-939.
3. Anderson JG, Taylor AG. Use of complementary therapies for cancer symptom management: results of the 2007 National Health Interview Survey. *J Altern Complement Med*. 2012;18(3):235-241.
4. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. *Integr Cancer Ther*. 2012;11(3):187-203.
5. Molassiotis A, Scott JA, Kearney N, et al. Complementary and alternative medicine use in breast cancer patients in Europe. *Support Care Cancer*. 2006; 14(3):260-267.
6. Sikorskii A, Wyatt GK, Siddiqi A, Tamkus D. Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial. *Evid Based Complement Alternat Med*. 2011;2011:734517. doi:10.1093/ecam/nep051.
7. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. *Support Care Cancer*. 2005;13(10):806-811.

8. Finnegan-John J, Molassiotis A, Richardson RE. A systematic review of complementary and alternative medicine interventions in the management of cancer-related fatigue. *BMJ Support Palliat Care*. 2011;1(suppl 1):A12. doi:10.1136/bmjspcare-2011-000020.34.
9. Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. *J Clin Oncol*. 2006;24(34):5457-5464.
10. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. *J Clin Psychiatry*. 2010;71(6):669-681.
11. Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. *Cancer J*. 2006;12(5):425-431.
12. Burns SJ, Harbuz MS, Hucklebridge F, Bunt L. A pilot study into the therapeutic effects of music therapy at a cancer help center. *Altern Ther Health Med*. 2001;7(1):48-56.
13. Hilliard RE. The effects of music therapy on the quality and length of life of people diagnosed with terminal cancer. *J Music Ther*. 2003;40(2):113-137.
14. Lin MF, Hsieh YJ, Hsu YY, Fetzer S, Hsu MC. A randomised controlled trial of the effect of music therapy and verbal relaxation on chemotherapy-induced anxiety. *J Clin Nurs*. 2011;20(7-8):988-999.
15. Bradt J, Goodill SW, Dileo C. Dance/movement therapy for improving psychological and physical outcomes in cancer patients. *Cochrane Database Syst Rev*. 2011;10(10):CD007103.
16. Jeong YJ, Hong SC, Lee MS, Park MC, Kim YK, Suh CM. Dance movement therapy improves emotional responses and modulates neurohormones in adolescents with mild depression. *Int J Neurosci*. 2005;115(12):1711-1720.
17. Sandel SL, Judge JO, Landry N, Faria L, Ouellette R, Majczak M. Dance and movement program improves quality-of-life measures in breast cancer survivors. *Cancer Nurs*. 2005;28(4):301-309.
18. West J, Otte C, Geher K, Johnson J, Mohr DC. Effects of Hatha yoga and African dance on perceived stress, affect, and salivary cortisol. *Ann Behav Med*. 2004;28(2):114-118.
19. Beebe A, Gelfand EW, Bender B. A randomized trial to test the effectiveness of art therapy for children with asthma. *J Allergy Clin Immunol*. 2010;126(2):263-266. doi:10.1016/j.jaci.2010.03.019.
20. Svensk AC, Oster I, Thyme KE, et al. Art therapy improves experienced quality of life among women undergoing treatment for breast cancer: a randomized controlled study. *Eur J Cancer Care (Engl)*. 2009;18(1):69-77.
21. Thyme KE, Sundin EC, Wiberg B, Oster I, Aström S, Lindh J. Individual brief art therapy can be helpful for women with breast cancer: a randomized controlled clinical study. *Palliat Support Care*. 2009;7(1):87-95.
22. Raglio A, Bellelli G, Traficante D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. *Alzheimer Dis Assoc Disord*. 2008;22(2):158-162.
23. Geue K, Goetze H, Buttstaedt M, Kleinert E, Richter D, Singer S. An overview of art therapy interventions for cancer patients and the results of research. *Complement Ther Med*. 2010;18(3-4):160-170.
24. Wood MJM, Molassiotis A, Payne S. What research evidence is there for the use of art therapy in the management of symptoms in adults with cancer? a systematic review. *Psychooncology*. 2011;20(2):135-145.
25. Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. *Cochrane Database Syst Rev*. 2011;8(8):CD006911.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264-269. W64.
27. Hedges LV, Olkin I. *Statistical Methods for Meta-analysis*. New York, NY: Academic Press; 1985.
28. Rosenthal R. *Meta-analytic Procedures for Social Research*. London, England: Sage Publications; 1991.
29. Puig A, Lee SM, Goodwin L, Sherrard PAD. The efficacy of creative arts therapies to enhance emotional expression, spirituality, and psychological well-being of newly diagnosed stage I and stage II breast cancer patients: a preliminary study. *Arts Psychother*. 2006;33(3):218-228. doi:10.1016/j.aip.2006.02.004.
30. Zimmerman L, Pozehl B, Duncan K, Schmitz R. Effects of music in patients who had chronic cancer pain. *West J Nurs Res*. 1989;11(3):298-309.
31. Kwekkeboom KL. Music versus distraction for procedural pain and anxiety in patients with cancer. *Oncol Nurs Forum*. 2003;30(3):433-440.
32. Bruera E, Willey J, Cohen M, Palmer JL. Expressive writing in patients receiving palliative care: a feasibility study. *J Palliat Med*. 2008;11(1):15-19.
33. Monti DA, Peterson C, Kunkel EJS, et al. A randomized, controlled trial of mindfulness-based art therapy (MBAT) for women with cancer. *Psychooncology*. 2006;15(5):363-373.
34. Smith M, Casey L, Johnson D, Gwede C, Riggan OZ. Music as a therapeutic intervention for anxiety in patients receiving radiation therapy. *Oncol Nurs Forum*. 2001;28(5):855-862.
35. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. *J Clin Epidemiol*. 1992;45(3):255-265.
36. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86(2):420-428.
37. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. *Statistician*. 1983;32(3):307-317.
38. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet*. 1986;1(8476):307-310.
39. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. *JAMA*. 1999;282(11):1054-1060.
40. Lipsey MW, Wilson DB. *Practical Meta-analysis*. Newbury Park, CA: Sage; 2001.
41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.
42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.
43. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50(4):1088-1101.
44. Rosenthal R, DiMatteo MR. Meta-analysis: recent developments in quantitative methods for literature reviews. *Annu Rev Psychol*. 2001;52(1):59-82.
45. Gleser LJ, Olkin I. Stochastically dependent effect sizes. In: Cooper H, Hedges LV, eds. *The Handbook of Research Synthesis*. New York, NY: Sage; 1994:339-355.
46. Lin KY, Hu YT, Chang KJ, Lin HF, Tsauo JY. Effects of yoga on psychological health, quality of life, and physical health of patients with cancer: a meta-analysis. *Evid Based Complement Alternat Med*. 2011;2011:659876. doi:10.1155/2011/659876.
47. Clark M, Isaacks-Downton G, Wells N, et al. Use of preferred music to reduce emotional distress and symptom activity during radiation therapy. *J Music Ther*. 2006;43(3):247-265.
48. Hanser SB, Bauer-Wu S, Kubicek L, et al. Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer. *J Soc Integr Oncol*. 2006;4(3):116-124.
49. de Moor C, Sterner J, Hall M, et al. A pilot study of the effects of expressive writing on psychological and behavioral adjustment in patients enrolled in a phase II trial of vaccine therapy for metastatic renal cell carcinoma. *Health Psychol*. 2002;21(6):615-619.
50. Dibbell-Hope S. The use of dance/movement therapy in psychological adaptation to breast cancer. *Arts Psychother*. 2000;27(1):51-68.
51. Shabanloei R, Golchin M, Esfahani A, Dolatkhan R, Rasoulani M. Effects of music therapy on pain and anxiety in patients undergoing bone marrow biopsy and aspiration. *AORN J*. 2010;91(6):746-751.
52. Ferrer AJ. The effect of live music on decreasing anxiety in patients undergoing chemotherapy treatment. *J Music Ther*. 2007;44(3):242-255.
53. Cassileth BR, Vickers AJ, Magill LA. Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. *Cancer*. 2003;98(12):2723-2729.
54. Sabo CE, Michael SR. The influence of personal message with music on anxiety and side effects associated with chemotherapy. *Cancer Nurs*. 1996;19(4):283-289.
55. Bulfone T, Quattrin R, Zanotti R, Regattin L, Brusaferrero S. Effectiveness of music therapy for anxiety reduction in women with breast cancer in chemotherapy treatment. *Holist Nurs Pract*. 2009;23(4):238-242.
56. Nguyen TN, Nilsson S, Hellstrom AL, Bengtson A. Music therapy to reduce pain and anxiety in children with cancer undergoing lumbar puncture: a randomized clinical trial. *J Pediatr Oncol Nurs*. 2010;27(3):146-155.
57. Stordahl JJ. *The Influence of Music on Depression, Affect, and Benefit Finding Among Women at the Completion of Treatment for Breast Cancer* [dissertation]. Coral Gables, Florida: University of Miami; 2009.
58. Li XM, Yan H, Zhou KN, Dang SN, Wang DL, Zhang YP. Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial. *Breast Cancer Res Treat*. 2011;128(2):411-419.
59. Rosenberg HJ, Rosenberg SD, Ernstoff MS, et al. Expressive disclosure and health outcomes in a prostate cancer population. *Int J Psychiatry Med*. 2002;32(1):37-53.
60. Huang S, Good M, Zauszniewski JA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. *Int J Nurs Stud*. 2010;47(11):1354-1362.
61. Gellaity G, Peters K, Bloomfield D, Home R.

- Narrowing the gap: the effects of an expressive writing intervention on perceptions of actual and ideal emotional support in women who have completed treatment for early stage breast cancer. *Psychooncology*. 2010;19(1):77-84.
62. Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. *J Consult Clin Psychol*. 2012;80(6):1007-1020.
 63. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: a systematic review. *J Pain Symptom Manage*. 2000;20(5):374-387.
 64. Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. *J Clin Oncol*. 2007;25(28):4387-4395.
 65. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. *Arch Intern Med*. 2010;170(4):321-331.
 66. Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2012;21(1):3-19.
 67. Herring MP, Puetz TW, O'Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012;172(2):101-111.
 68. Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS. Exercise interventions for cancer survivors: a meta-analysis of quality of life outcomes. *Ann Behav Med*. 2011;41(1):32-47.
 69. Stuckey HL, Nobel J. The connection between art, healing, and public health: a review of current literature. *Am J Public Health*. 2010;100(2):254-263.
 70. Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. *Am J Prev Med*. 2012;43(2):e1-e24. doi:10.1016/j.amepre.2012.04.027.
 71. Broom A, Tovey P. The dialectical tension between individuation and depersonalization in cancer patients' mediation of complementary, alternative, and biomedical cancer treatments. *Sociology*. 2007;41(6):1021-1039. doi:10.1177/0038038507082313.
 72. Smithson J, Paterson C, Britten N, Evans M, Lewith G. Cancer patients' experiences of using complementary therapies: polarization and integration. *J Health Serv Res Policy*. 2010;15(suppl 2):54-61.
 73. Smithson J, Britten N, Paterson C, Lewith G, Evans M. The experience of using complementary therapies after a diagnosis of cancer: a qualitative synthesis. *Health (London)*. 2012;16(1):19-39.
 74. Lo-Fo-Wong DN, Ranchor AV, de Haes HC, Sprangers MA, Henselmans I. Complementary and alternative medicine use of women with breast cancer: self-help CAM attracts other women than guided CAM therapies. *Patient Educ Couns*. 2012;89(3):529-536. doi:10.1016/j.pec.2012.02.019.
 75. O'Connor EL, White KM. Intentions and willingness to use complementary and alternative medicines: what potential patients believe about CAMs. *Complement Ther Clin Pract*. 2009;15(3):136-140.
 76. Brody HB, Brody D. Placebo and health, II: three perspectives on the placebo response: expectancy, conditioning, and meaning. *Adv Mind Body Med*. 2000;16(3):216-232.
 77. Walach H, Jonas WB. Placebo research: the evidence base for harnessing self-healing capacities. *J Altern Complement Med*. 2004;10(suppl 1):S103-S112.
 78. Oken BS. Placebo effect: Clinical perspectives and potential mechanisms. In: Oken BS, ed. *Complementary Therapies in Neurology: An Evidence-Based Approach*. New York, NY: Parthenon Publishing Group; 2004:247-274.
 79. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? *Ann Intern Med*. 2002;136(11):817-825.
 80. O'Callaghan V. Patients' perceptions of complementary and alternative medicine. *Can Forum*. 2011;35(1):44-47. http://www.cancerforum.org.au/Issues/2011/March/Forum/Patients_perceptions_complementary_alternative.htm. Accessed April 5, 2013.
 81. Kemper KJ, Wornham WL. Consultations for holistic pediatric services for inpatients and outpatient oncology patients at a children's hospital. *Arch Pediatr Adolesc Med*. 2001;155(4):449-454.
 82. Paice JA. Assessment of symptom clusters in people with cancer. *J Natl Cancer Inst Monogr*. 2004;2004(32):98-102.

INVITED COMMENTARY

Creative Arts Therapies Defined

A diagnosis of cancer and subsequent treatments may result in significant emotional, physical, and social suffering, placing cancer survivors at greater risk for mental health issues.^{1,2} Therefore, the care of cancer patients should incorporate services that help meet patients' psychological, social, and spiritual needs. Creative arts therapies (CATs), such as dance/movement, music, art, poetry, drama, and psychodrama, are increasingly used to aid in the care of cancer patients and in their recovery. The results of several systematic reviews, as referenced in the study by Puetz et al³ have reported small to moderate effects of music, art, and dance/movement therapies on a variety of psychological outcomes in cancer

patients. The systematic review by Puetz and colleagues aims to expand the existing evidence base by identifying potential moderators of the efficacy of CATs during and after cancer treatment.

The review included 27 randomized clinical trials (RCTs) that examined the effects of arts interventions (music, art, dance, and expressive writing) on psychological outcomes in 1576 cancer patients. The pooled estimates indicate that arts interventions significantly reduced anxiety, depression, and pain and improved the quality of life in cancer patients. The results indicate no evidence of an effect on fatigue. Moderator analyses suggest greater pain reductions during inpatient treatment and for homogeneous cancer groups. In addition,

the authors report that anxiety reduction was greater for those studies "in which the arts intervention was administered by a non-CAT therapist compared with those delivered by a CAT therapist."³

The continuum of care in arts in health care practices ranges from performances for patients by artists to focused individualized psychotherapeutic CAT interventions. We value and applaud the use of the arts and creative processes across this continuum because they enhance patient care and well-being. Research on the efficacy of these interventions, however, requires clarity about the nature of the interventions themselves. Unfortunately, the analysis by Puetz et al³ offers no operational definition of CATs. Instead, the authors use